Allergy

Phase 3 RAPIDe-3 data show rapid, sustained relief of hereditary angioedema attacks; PDUFA date set for April 23, 2027.

A roundup of key FDA approvals, pipeline advances, and updated guidelines shaping allergy and HAE care in the first half of 2026.

FDA epinephrine updates, phase 3 HAE data on lonvo-z, and new food allergy prevention research from April through June 2026.

HAE gene editing, peanut patch trials, CSU sequencing, and EAC 2026 highlights in this allergy/immunology roundup for clinicians.

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

Phase 3 VITESSE subgroup data show response rates of 46% to 48% in children with peanut allergy and concomitant asthma, atopic dermatitis, or food allergies, says David Fleischer, MD.

Douglas Mack, MD, discusses the upcoming phase 2 THRIVE trial assessing the Viaskin Peanut patch in infants aged 6 through 12 months with peanut allergy.

From a one-time CRISPR therapy cutting HAE attacks by 87% to CSU biomarkers and emerging ILIT research, here are the 5 allergy stories worth catching up on from May 2026.

At EAC 2026, Dartmouth Children's Health allergist Marcus Shaker, MD, outlined a framework built on shared decision-making for families navigating food allergy in infancy.

Jonathan Bernstein, MD, discusses remibrutinib, c-kit inhibitors, and the current limits of biomarker-guided decision-making in chronic spontaneous urticaria.

Marcus Shaker, MD, discusses early allergen introduction, food allergy prevention, and the role of routine testing at EAC 2026.

Bernstein discussed treatment sequencing, biomarker use, and evolving chronic spontaneous urticaria management strategies during an interview at EAC 2026.

Bernstein discussed the evolving role of biomarkers in chronic spontaneous urticaria at EAC 2026.

In this Q&A, Christopher Brooks, MD, discusses advancing research on intralymphatic immunotherapy for environmental and, more recently, food allergies.

Experts weigh in on a rapidly evolving treatment landscape, from a first-line oral option to a one-time CRISPR therapy showing 87% attack reduction.